Compare 8x8 Inc (EGHT) vs Mesoblast Limited (MESO) Price & Performance

EGHT (8x8, Inc.) trades at $2.035, down 6.22% on the day. The stock shows a bullish technical signal from moving averages, though oscillators are neutral. Fundamentally, the company reported a net loss of $27.21M for 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights product innovation with AI Routing and Pulse solutions, and the company was named a 2026 MetriStar Top Provider for CPaaS. Revenue grew to $715.07M in 2025, with a forecasted return to profitability in 2026.

The outlook hinges on the company's transition to profitability, projected for 2026 with a net profit of $2M. Investment opportunities include continued revenue growth, successful execution of new AI-driven products, and cost discipline. Key risks are the high P/E ratio of 197, significant long-term debt of $338.37M, and the challenge of sustaining recent earnings beats. Analyst sentiment is mixed but leans positive, with 39% Buy ratings.

MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.

The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.